Taken together, this data indicates LAG3 acts as an immune-checkpoint receptor quenching the immune response, becoming a very attractive “druggable” receptor for cancer immunotherapy, especially in combination with PD1 and/or CTLA4 blockade. The gene discussed is CTLA4; the disease is cancer.